TCG Crossover

TCG Crossover, based in Palo Alto, California, is a prominent healthcare investment firm specializing in late-stage private and public biotechnology companies. As the crossover fund of The Column Group (TCG), which is renowned for its company creation model in early-stage biotech, TCG Crossover extends this expertise to later-stage opportunities. The firm is dedicated to advancing disruptive medicines by providing significant capital and strategic support to companies navigating clinical development, regulatory milestones, and commercialization. Its investment philosophy centers on identifying and backing innovative therapeutic platforms and products with the potential to address significant unmet medical needs.

The firm's strategy involves making substantial equity investments in companies that are typically approaching or have achieved clinical proof-of-concept, or are poised for public market entry. TCG Crossover leverages the deep scientific and operational expertise of its parent, The Column Group, offering portfolio companies not just capital but also strategic guidance, access to a vast network of industry experts, and support in navigating complex drug development pathways. This collaborative approach aims to accelerate the development and commercialization of groundbreaking therapies, ensuring that promising scientific innovations reach patients efficiently.

TCG Crossover operates with considerable financial firepower, having successfully raised substantial capital for its funds. For instance, its second dedicated crossover fund, TCG Crossover II, closed in 2022 with $2.5 billion in commitments, following its inaugural $1.2 billion fund in 2020. This significant capital base allows TCG Crossover to make impactful investments, with typical first checks ranging from $50 million to $250 million. These investments often represent lead or significant participation in large financing rounds, including late-stage private rounds, pre-IPO financings, and public equity investments (PIPEs). The firm's capacity to deploy substantial capital positions it as a key partner for biotech companies seeking to scale operations, fund extensive clinical trials, or prepare for public market liquidity.